Shazamstocks.com Announces Profile Launch of BrainStorm Cell Therapeutics
Monday February 27, 9:00 am ET
WELLINGTON, Fla., Feb. 27, 2006 (PRIMEZONE) -- Ken Weiner, publisher of Shazamstocks.com, today announced profile coverage of BrainStorm Cell Therapeutics (OTC BB:BCLI.OB - News). The profile is a comprehensive look at the company's growth initiative. You can view the complete profile at shazamstocks.com.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is an emerging company developing the neural-like stem cell therapeutic product NurOwn(tm), based on autologous bone marrow derived stromal cells, for treatment of neurodegenerative diseases. NurOwn(tm) patent pending technology is based on discoveries made by the team of prominent neurologist, Prof. Eldad Melamed, Head of Neurology at Rabin Medical Center, and expert cell biologist Dr. Daniel Offen, at the Felsenstein Medical Research Center of Tel-Aviv University, enabling the differentiation of bone marrow derived stem cells into functional neurons and astrocytes, as demonstrated in animal models. The company holds rights to develop and commercialize the technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University. The company's initial focus is on developing treatments for Parkinson's Disease.
About Shazamstocks.com
Shazamstocks.com publishes profiles on up and coming publicly traded companies. Shazamstocks.com is one of the nation's top Internet destinations for small cap stock information. To feature your company, please call Ken Weiner, our Publisher at (561) 793-2665 or email editor@shazamstocks.com.
Disclosure: Shazamstocks.com has been compensated by a third party Tayside Corp Up to 150,000 restricted shares of BCLI. Details can be found at shazamstocks.com
biz.yahoo.com
Dubi |
